Esperion Therapeutics is a drug manufacturers - specialty & generic business based in the US. Esperion Therapeutics shares (ESPR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.41 – an increase of 8.07% over the previous week. Esperion Therapeutics employs 240 staff and has a trailing 12-month revenue of around $295.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.41 |
|---|---|
| 52-week range | $1.15 - $3.40 |
| 50-day moving average | $1.95 |
| 200-day moving average | $2.22 |
| Wall St. target price | $7.51 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.63 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.15 from 2024-11-18
| 1 week (2024-11-14) | 2.38% |
|---|---|
| 1 month (2024-10-21) | 4.37% |
| 3 months (2024-08-21) | 22.16% |
| 6 months (2024-05-21) | -10.79% |
| 1 year (2023-11-21) | 80.67% |
|---|---|
| 2 years (2022-11-21) | -68.01% |
| 3 years (2021-11-19) | 7.41 |
| 5 years (2019-11-21) | 47.08 |
Valuing Esperion Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Esperion Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Esperion Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.5 million.
The EBITDA is a measure of a Esperion Therapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $295.5 million |
|---|---|
| Gross profit TTM | $-70,419,000 |
| Return on assets TTM | 3.84% |
| Return on equity TTM | -260.79% |
| Profit margin | -29.37% |
| Book value | $-1.89 |
| Market Capitalization | $413.8 million |
TTM: trailing 12 months
We're not expecting Esperion Therapeutics to pay a dividend over the next 12 months.
Esperion Therapeutics's shares were split on a 1:6 basis on 10 June 2013 . So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Esperion Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Esperion Therapeutics shares which in turn could have impacted Esperion Therapeutics's share price.
Over the last 12 months, Esperion Therapeutics's shares have ranged in value from as little as $1.15 up to $3.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Esperion Therapeutics's is 0.954. This would suggest that Esperion Therapeutics's shares are less volatile than average (for this exchange).
Esperion Therapeutics, Inc. , a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co. , Ltd; and Daiichi Sankyo Europe GmbH.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.